Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 12

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 12
---
commercial applications of LineaDNA with our future planned availability of LineaDNA manufactured under GMP suitable for use as, or incorporation
into, a biologic, drug substance and/or drug product at planned GMP Site 2. Planned GMP Site 2 may also be used for additional LineaDNA
IVT template manufacturing if customer demand exceeds capacity of GMP Site 1. In addition, we believe GMP Site 1 is capable of manufacturing
LineaDNA for use as, or incorporation into, a biologic, drug substance, and/or drug product manufacturing via facility upgrades to its
existing footprint.

Our current plan is: (i) through our
Linea IVT platform and planned near term future GMP manufacturing capabilities for IVT templates at GMP Site 1 to secure commercial-scale
supply contracts with clinical and commercial mRNA and/or self-amplifying mRNA (“sa-RNA”) manufacturers for LineaDNA IVT
templates and/or Linea RNAP as critical starting materials; (ii) to utilize our current GLP production capacity for non-IVT template
applications to secure supply and/or development contracts with pre-clinical therapy developers that use DNA in their therapy manufacturing,
and (iii) upon our development of our planned future LineaDNA production under GMP suitable for use as, or incorporation into, a
biologic, drug substance and/or drug product at planned GMP Site 2 and/or our upgrade to GMP Site 1, to convert existing and new LineaDNA
customers into large-scale supply contracts to supply LineaDNA for clinical and commercial use as, or incorporation into, a biologic,
drug substance and/or drug product in a wide range of nucleic acid therapies. In addition, the Company plans to utilize its planned DNA
manufacturing capabilities in GMP Site 1 and/or GMP Site 2 to convert new and existing LineaDNA IVT template customers to LineaIVT platform
customers to increase the Company’s mRNA-related TAM.

Until our GMP Site 1 to produce DNA critical
starting materials (DNA IVT templates) for mRNA manufacturing is operational we will not be able to realize significant revenues from
this business. If we were to expand our facilities to enable GMP production of LineaDNA for use as, or incorporation, into a biologic,
drug substance and/or drug product as planned for GMP Site 2, the additional CAPEX may be up to approximately $10 million which would
require additional funding.